関連する実験動画
Updated: Aug 15, 2026

09:36
Assessment of Child Anthropometry in a Large Epidemiologic Study
Published on: February 2, 2017
肥満のリスクのある子供の代謝率と身体的発達
M Griffiths1, P R Payne, A J Stunkard
1Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, UK.
Lancet (London, England)
|July 14, 1990
まとめ
親の肥満は,性によって子供の成長に影響を及ぼします. 男の子は親の肥満に関連したより速い成長を示したが,女の子の成長は子供のエネルギー摂取と結びついていた.
科学分野:
- 小児内分泌学について
- 人間の成長と発展
- メタボリック・ヘルス (代謝の健康)
背景:
- 幼児の肥満は,長期的な健康への影響を及ぼす可能性のある懸念が高まっています.
- 親の肥満は,小児肥満の既知の危険因子です.
- 成長と代謝率に影響を与える性特異的要因を理解することは,早期介入にとって極めて重要です.
研究 の 目的:
- 子どもの成長と代謝率に対する親の肥満の長期的な影響を調査する.
- 親の肥満,子供のエネルギー摂取量,青少年の発達との関係における性差を調べる.
- 肥満に易感する子供の休息代謝率 (RMR) と成長パターンとの関連性を調べる.
主な方法:
- 肥満や正常体重の親の子どもを3~5歳から青春期 (12年後に) まで追跡した長期的研究.
- 幼児期の代謝率 (RMR) と食物摂取量の評価
- 成長パラメータ (身長,体重,肥満) と青春期のRMR変化の分析,性別別層化.
主要な成果:
- 思春期の男の子では,親の肥満はより急速な成長を予測したが,肥満の増加は予測されなかった.
- 少女の場合は,子供の頃のエネルギー摂取が体サイズと肥満を予測し,親の肥満は予測値が低い.
- RMR/kg体重の減少は,肥満家庭の男の子の早期に観察され,早期成長と潜在的に関連しています.
結論:
- 親の肥満と子供のエネルギー摂取が,青少年の成長と身体構成にどのように影響するかには,重要な性差が存在します.
- 少女の早期熟成は,成長と肥満の予測要因における観察された性差異を説明する可能性がある.
- 幼児期の低RMR/kg体重は,肥満に易感する子供の早期の成長パターンと関連している可能性があります.
関連する概念動画
Nature and Nurture
Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
Overview of Protein Metabolism
Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...

